There are currently 874 clinical trials in Indianapolis, Indiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Indiana University, Indiana University Melvin and Bren Simon Cancer Center, Riley Hospital for Children and Indiana University Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: NAVREF - Indiana Institute for Medical Research (IIMC), Indianapolis, Indiana +2 locations
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
The Ailliance Post-Market Clinical Study
NCT05856370
Recruiting
The purpose of this clinical study is to collect performance and safety data for post-market Medtronic devices indicated for cranial and/or spinal indication(s). Subjects are enrolled and followed postoperatively for up to 24 months. The Ailliance clinical study is intended to collect data congruous with routine clinical care practices.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: The Orthopaedic Research Foundation (OrthoIndy), Indianapolis, Indiana
Conditions: Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma, Spinal Tumor Case
Register for Updates
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT03827798
Recruiting
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533, LYS006, MAS825 , LOU064 and VAY736 in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2024
Locations: Dawes Fretzin Clinical Rea Group, Indianapolis, Indiana
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
NCT05966740
Recruiting
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
Gender:
All
Ages:
Between 3 months and 12 years
Trial Updated:
04/25/2024
Locations: Indiana Hemophilia & Thrombrosis Center, Indianapolis, Indiana
Conditions: Venous Thromboembolism
Register for Updates
Building Emotional Self-Awareness Teletherapy (BEST)
NCT05623046
Recruiting
To examine the feasibility, acceptability, and preliminary efficacy of a remotely delivered intervention for civilians and service members with mild traumatic brain injury (mTBI) who have difficulty recognizing and regulating their emotions. Post-treatment outcomes of interest include emotional self-awareness and regulation, resiliency, and affective symptoms.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Concussion, Mild, Concussion, Brain, Concussion, Severe, Concussion, Intermediate, Concussion; Syndrome, Concussion Injury of Cerebrum, Concussion With Brief Loss of Consciousness, Alexithymia
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
04/25/2024
Locations: Research Site, Indianapolis, Indiana
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
Evaluate Pharmacokinetics and Safety of Slow Release DHEA
NCT05623059
Recruiting
This is a study to look at pharmacokinetic levels of different doses of slow release DHEA in subjects with severe asthma.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
04/25/2024
Locations: Riley Hospital for Children, Indianapolis, Indiana +1 locations
Conditions: Asthma, Genotype
Register for Updates
Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT04704921
Recruiting
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, b... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
04/25/2024
Locations: Midwest Eye Institute, Indianapolis, Indiana
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV
Register for Updates
Sex Differences in the Response to Abstinence From Alcohol.
NCT03827460
Recruiting
In laboratory animals, repeated cycles of abstinence from and return to alcohol drinking can lead to changes in alcohol intake. In a study of the effect of abstinence on drinking in humans, the investigators found evidence that abstinence affects drinking differently in women compared to men. In the present study, the investigators propose to study how men and women respond to abstinence, and whether this information can be used to improve intervention and prevention strategies.
Gender:
All
Ages:
Between 21 years and 35 years
Trial Updated:
04/24/2024
Locations: University Hospital, Indianapolis, Indiana
Conditions: Alcohol Use Disorder
Register for Updates
A Nasal Treatment for COVID-19
NCT05799521
Recruiting
The goal of this study is to test an investigational new inhaled medication called Optate.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/24/2024
Locations: Riley Hospital for Children, Indianapolis, Indiana
Conditions: COVID-19
Register for Updates
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
NCT05548283
Recruiting
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonar... Read More
Gender:
All
Ages:
6 years and above
Trial Updated:
04/24/2024
Locations: Indiana University Medical Center, Indianapolis, Indiana +1 locations
Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Register for Updates
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
NCT05860296
Recruiting
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the stud... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Community Health Network, Indianapolis, Indiana
Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Register for Updates